Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Launched by MANSOURA UNIVERSITY · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called dapagliflozin in adults with chronic kidney disease (CKD) who also have anemia, a condition where you don't have enough healthy red blood cells. Dapagliflozin is usually used to help manage type 2 diabetes, but recent research suggests it might also help improve hemoglobin levels in patients with CKD. The trial aims to see if dapagliflozin can effectively raise hemoglobin levels, which could be beneficial for those struggling with anemia due to their kidney condition.
To participate in this trial, you must be an adult aged 18 or older, have CKD stage III or IV, and have anemia with a hemoglobin level below 11.5 g/dL. Additionally, you should already be receiving treatment that helps stimulate the production of red blood cells. However, if your anemia is caused by other conditions, or if you have certain health issues like severe infections or recent heart problems, you may not be eligible. Participants can expect to receive the study medication and be monitored regularly to assess its effects on their anemia. This trial is currently recruiting, and it welcomes all genders.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • 1. Adults aged ≥ 18 years with CKD stage III or IV.
- • 2. Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
- • 3. Patients are receiving erythropoiesis-stimulating agent therapy.
- • Exclusion criteria
- • 1. Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
- • 2. Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
- • 3. Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
- • 4. Patients with current malignancies or a history of malignancy within the past 2 years.
- • 5. Diagnosed with pure red cell aplasia.
- • 6. Patients with severe gastrointestinal bleeding.
- • 7. Pregnant or lactating females.
About Mansoura University
Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mansoura, , Egypt
Patients applied
Trial Officials
Noha O. Mansour, Ph.D.
Principal Investigator
Mansoura University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported